An anti-aging drug must delay cancer longer than therapies extend life after diagnosis, Ira Pastor argues

An anti-aging drug must delay cancer longer than therapies extend life after diagnosis, Ira Pastor argues

On October 11, Ira Pastor, host of a science and technology podcast, proposed a benchmark for anti-aging drugs in a debate about whether aging will be reversed.

For cancer, two timeframes matter. The first is before the disease: by how many years a drug pushes back diagnosis, say from age 65 to 80. The second is after diagnosis: by how much treatment extends a patient's life. Pastor proposes comparing these two timeframes.

The account @rand_longevity asked on X: "Do you think aging will be reversed in your lifetime?" Pastor replied that this is "not quite the right question, and it is incomplete." The right question, he said, is different: will any of the "aging reversal" tools delay the diseases that kill us (cancer and heart disease above all) appreciably longer than new precision therapies extend life after diagnosis.

The geroscience hypothesis holds that targeting the mechanisms of aging could delay many age-related diseases at once. From this, according to Pastor, influential figures in the longevity industry conclude that diseases can be pushed back indefinitely or forever, and they sell this dream. His example: cancer will not appear until age 150, heart disease until 180.

"There is no evidence anywhere that this is the case, and we will not know even if aging reversal tools become available to us for many decades."

Bill Walker (@BWalkerTTAGGG) wrote in reply that one thing is known for certain: bowhead whales, which have more than a thousand times as many cells as humans, live at least 230 and possibly 268 years.

"We don't even need to invent longevity technology, we just need to borrow it from other mammals."

Cell count is linked to cancer: a tumor grows from a single cell that has accumulated mutations, and in an animal with a thousandfold greater number of cells one would expect the risk to be higher. Peto's paradox is that large species do not develop cancer more often than small ones. A 2022 paper in Nature confirmed this paradox, while a 2025 analysis of 292 vertebrate species did not confirm it. The figure of 268 years is a genome-based estimate: a 2019 paper in Scientific Reports estimated the whale's maximum lifespan this way. The oldest whale whose age could be determined was estimated at 211 years as of 2019; the number 230 does not appear in the paper.

Pastor replied to Walker with "True," but added that this is exactly why the question is so incomplete. Creating a "gerotherapeutic," a drug targeting aging mechanisms that would attempt in human clinical trials to replicate the whale's DNA repair and slow, cold-adapted metabolism, is one thing. Showing that it can delay cancer in humans longer than any combination of current therapies extends life after diagnosis is another. Among those therapies he listed immunotherapy, re-engineered immune cells from the patient, personalized vaccines, antibody-drug conjugates carrying a chemotherapeutic payload, radioligand therapies, and bispecific antibodies targeting two proteins at once.

An example of post-treatment survival comes from immunotherapy for melanoma, a skin cancer. In the final ten-year analysis of a clinical trial, among previously untreated patients with advanced melanoma, half of those who received nivolumab plus ipilimumab survived at least 71.9 months, nearly six years, while half of those who received ipilimumab alone, approved in 2011 before nivolumab, survived at least 19.9 months. At ten years, 43 out of 100 patients in the first group and 19 out of 100 in the second were alive.

Pastor concluded:

"This is the question the industry really needs to answer (cancer and heart disease first). Everything else is hype."